# Filing Detail

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-009809
Filing Date
2024-02-01
Accepted
2024-02-01 16:15:34
Documents
61
Period of Report
2023-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-K | abio-20231231.htm iXBRL | 10-K | 2058310
2 | EX-19 | abio-ex19.htm | EX-19 | 106748
3 | EX-23.1 | abio-ex23_1.htm | EX-23.1 | 3372
4 | EX-31.1 | abio-ex31_1.htm | EX-31.1 | 12399
5 | EX-31.2 | abio-ex31_2.htm | EX-31.2 | 12382
6 | EX-32.1 | abio-ex32_1.htm | EX-32.1 | 10187
7 | EX-97 | abio-ex97.htm | EX-97 | 47091
| Complete submission text file | 0000950170-24-009809.txt |  | 6562239

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | abio-20231231.xsd | EX-101.SCH | 896924
63 | EXTRACTED XBRL INSTANCE DOCUMENT | abio-20231231_htm.xml | XML | 755086

Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-22873 | Film No.: 24587126
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)